Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. - Wikidata - wikimedia - TriplyDB

Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia.

Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia.

http://www.wikidata.org/entity/Q37347515

about

Pediatric AML: From Biology to Clinical Management Childhood acute myeloid leukaemia Phase II study of 2-chlorodeoxyadenosine plus idarubicin for children with acute myeloid leukaemia in first relapse: a paediatric oncology group study.Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study.Challenging issues in pediatric oncology Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant How I treat Langerhans cell histiocytosis.Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.Pediatric acute myeloid leukemia.Novel therapies for children with acute myeloid leukaemia.Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments.Inching toward cure of acute myeloid leukemia: a summary of the progress made in the last 50 years.Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia.Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?Transplantation of CD3/CD19 depleted allografts from haploidentical family donors in paediatric leukaemia.Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia.Use of clofarabine for acute childhood leukemia.Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia.Clofarabine in combination with pegylated asparaginase in the frontline treatment of childhood acute lymphoblastic leukaemia: a feasibility report from the CoALL 08-09 trial.HLA haploidentical hematopoietic cell transplantation using clofarabine and busulfan for refractory pediatric hematological malignancy.High proportion of CD34+/CD38-cells is positively correlated with poor prognosis in newly diagnosed childhood acute lymphoblastic leukemia.Acute myeloid leukemia in children: Current status and future directions.Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol.

P2860

Q26799773-CAF0A01C-1C3A-4A27-AF08-119FDC909D87 Q27005960-F218D9AC-73C2-4F05-95FE-1B9699E25C1E Q33400806-863D22C6-8B13-44EB-B86E-03D663091322 Q33828575-A0A447D4-05EB-4478-85C7-F939EDC860A2 Q35060679-BA280032-3A77-467D-9B98-E9DCE8E6D821 Q35136616-9AFFA384-A842-4B58-901B-0182D073F64B Q35572057-837C7513-CAD5-4760-BC3C-62EB0C28663B Q35602419-28216346-0262-4998-B4E4-C15E0AEC37EB Q35770734-0A23A4D1-D180-42F3-94AB-5BAD5F88544F Q35820361-8AC65775-8C46-4470-AF97-4AED31481606 Q36176670-CA08C018-1BE2-4C10-A8EC-37AFC6B49E54 Q37140698-5C5C8CC6-C91D-45CD-8383-1AEC4DF8B641 Q37988570-6612CE21-D8DA-418D-AB7F-78E628F75D2A Q38096798-AF8B38F0-F624-4A7E-BDFD-3776293CE84F Q38097334-3D2EED33-1D29-4E3F-B8CB-60DFCD0265F1 Q38155455-39034BD0-6CFD-4E77-BCAC-7F1EDEE096E7 Q38232465-C7DF17A3-7E69-49C2-94FC-AE876E0895C2 Q38392656-D8F49BE7-5E93-4F4E-8B3A-2773A78799B8 Q39380445-697A5EFA-DDC4-4712-B2E2-9130941DD1DB Q40174651-6CC6F479-AF61-4E0C-8F4A-31E4C6E95EC7 Q41087485-95872C1F-CC8B-48F5-BB75-D45AA3A0C827 Q42737704-46D5B448-92BE-42F2-8762-E9EC1B56AA14 Q44646134-C61E8522-41B1-4A66-9357-42ECE43DB4D4 Q46971601-8639D093-EBAF-4769-B3C1-72F15937A56D Q48254230-F0FB0352-264B-4C58-A8E6-4C06A34731EA Q50962385-294A7528-5F18-489A-AFE0-5B7E8DE8C26A Q52897332-F6EDCBB2-4064-42DB-87E7-93AB2C6C3BF9 Q54207519-A89148BD-BE7D-4D03-B9B3-F31033BFCA57 Q54342479-9568DBB7-C79D-41F9-B30F-50C49AE8D2EF

P2860

Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia.

http://www.wikidata.org/entity/Q37347515

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 03 August 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Phase II study of clofarabine ...... lapsed acute myeloid leukemia.

@en

Phase II study of clofarabine ...... lapsed acute myeloid leukemia.

@nl

type

label

Phase II study of clofarabine ...... lapsed acute myeloid leukemia.

@en

Phase II study of clofarabine ...... lapsed acute myeloid leukemia.

@nl

prefLabel

Phase II study of clofarabine ...... lapsed acute myeloid leukemia.

@en

Phase II study of clofarabine ...... lapsed acute myeloid leukemia.

@nl

P1433

Q37347515-C89735B5-ECF2-4D3F-8FB9-9E92360FFF21

P1476

Q37347515-B8CB7C6C-E838-4B2A-AE1D-A2CB09935035

P2093

Q37347515-03446336-8716-427C-A2FD-DD727163EA96

Q37347515-4A15AC9A-4831-4BF0-B32C-A8B38A4EA6BB

Q37347515-571589DF-0151-4594-A663-699045E4340C

Q37347515-7589F85D-8C0F-460C-9F98-E21CB1EF6AA0

Q37347515-80F2B9FE-8722-4E8A-8C52-C18166247DEC

Q37347515-81BB7F1C-635E-4B31-95E3-6458B0BAE36F

Q37347515-97501A25-EA2A-485D-B52F-C7711DFBB8B2

Q37347515-A5657430-2179-4E20-8791-960B2408B1C0

Q37347515-A816AF1F-89FF-49F8-9C4D-95F5AA7A70B2

Q37347515-A9835891-5A57-4EE1-80CB-6DA877371DD0

P2860

Q37347515-091F8A7F-0980-4655-9C22-2EEA656B34DB

Q37347515-2DBA4116-62B7-4415-98D2-FAE3EC3EB03B

Q37347515-33D5D977-5538-4DD9-BEC6-C9A13EBAA0BA

Q37347515-35396202-A334-41C7-85D8-65B0F2A39DB2

Q37347515-42D022C9-8F8C-453F-9A00-F744635CA009

Q37347515-4E11C4F1-D36B-49CE-951C-02C2ADF5B12F

Q37347515-59348229-D951-4BD4-8BC5-0B19A474E89D

Q37347515-67BA8E6F-1C68-4350-99DC-F29735F12EDE

Q37347515-6C15DA3B-1931-46FE-97FC-B7012830CD22

Q37347515-701F68F3-67E7-4778-B62A-20CF89C94156

P304

Q37347515-A4C117F1-DAE2-45A2-ABDF-29D8ECA13D34

P31

Q37347515-EDD60F40-B333-4595-9BCC-0E187CCAF3AF

P356

Q37347515-887B9DAF-E2A5-4D97-BC02-AF8D6A4E394F

P407

Q37347515-AB239C7D-3A18-48D1-9A12-1103F16953DA

P433

Q37347515-B931E67B-1A1A-4855-AED9-F7D89891E0B1

P478

Q37347515-0FED96F1-CF72-4524-85D0-59A21E0E299C

P50

Q37347515-0930BF8A-F68C-46B6-B318-96617DB5FB94

P577

Q37347515-D20B6EEB-1DA7-40D3-AB7C-CC3BF2CD968A

P698

Q37347515-6E4997A6-7B5A-4F2E-8971-846342ED70E2

P921

Q37347515-7034538E-ACD9-4926-86AC-0CF941FE10C4

Q37347515-8FA4D4F3-CCCD-4E87-ACA6-F3B627D834F8

P932

Q37347515-581AD5EE-4856-41EB-9EC9-952F406A069D

P356

JCO.2008.18.8706

P1433

Journal of Clinical Oncology

P1476

Phase II study of clofarabine ...... lapsed acute myeloid leukemia.

@en

P2093

Arnold Altman

http://www.w3.org/2001/XMLSchema#string

Bassem Razzouk

http://www.w3.org/2001/XMLSchema#string

Edythe Albano

http://www.w3.org/2001/XMLSchema#string

Kim Ritchey

http://www.w3.org/2001/XMLSchema#string

Kimo Stine

http://www.w3.org/2001/XMLSchema#string

Laurel Steinherz

http://www.w3.org/2001/XMLSchema#string

Lisa Bomgaars

http://www.w3.org/2001/XMLSchema#string

Lori Luchtman-Jones

http://www.w3.org/2001/XMLSchema#string

Michael Rytting

http://www.w3.org/2001/XMLSchema#string

Peter Steinherz

http://www.w3.org/2001/XMLSchema#string

P2860

Fifty years of studies of the biology and therapy of childhood leukemia

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

Progress and controversies in the treatment of pediatric acute myelogenous leukemia.

Recent advances in pediatric acute lymphoblastic and myeloid leukemia.

Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives.

A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias.

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.

Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.

Biochemical modulation of cytarabine triphosphate by clofarabine.

Childhood leukemias.

P304

4392-4397

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.18.8706

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-08-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19652076

http://www.w3.org/2001/XMLSchema#string

P921

P932

2744276

http://www.w3.org/2001/XMLSchema#string